of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve

Launched by BENI-SUEF UNIVERSITY · May 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the effects of three supplements—Myo-inositol, melatonin, and co-enzyme Q10—on improving ovarian reserve, which is important for women undergoing IVF (in vitro fertilization). The trial specifically targets women who are considered poor responders, meaning they have a low number of eggs available for fertilization. Researchers want to see if these supplements can help increase the number of healthy eggs and improve the chances of a successful pregnancy through IVF.

To be eligible for this study, participants must be infertile women who show signs of poor ovarian response, such as having fewer than 7 antral follicles (small fluid-filled sacs in the ovaries) or low levels of a hormone called anti-Mullerian hormone. However, women with certain health issues, such as thyroid problems or pelvic conditions, as well as those with male factor infertility, will not be able to participate. If you join the trial, you will be part of a group that receives these supplements to see how they affect your ovarian function, and you will be closely monitored throughout the study. Keep in mind that this trial has not yet started recruiting participants.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Infertile women who have one of the criteria of poor ovarian response as follows;
• • Antral follicle count less than 7
• • Anti-Mullerian hormone level Less than 1.2 ng/ml
• Exclusion Criteria:
• • 1. Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction
• • 2. Any pelvic pathology such as hydrosalpinx, uterine anomaly.
• • 3. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia